


# PatientBase

Customizable Epidemiological Data



## 2012

### Indication Name

*Subpopulation Scheme: Subpopulation Name*

### Cancer

#### Acute Lymphoblastic Leukemia

*Age group: Adult*

*Age group: Pediatric*

*Drug-Treatable Populations: First line (pediatric)*

*Drug-Treatable Populations: First line (adult)*

*Drug-Treatable Populations: Relapsed (pediatric)*

*Drug-Treatable Populations: Relapsed (adult)*

#### Acute Myeloid Leukemia

*Subtype: Acute promyelocytic leukemia*

*Subtype: Other subtypes*

*Drug-Treatable Populations: First line (exc. acute promyelocytic leukemia)*

*Drug-Treatable Populations: Relapsed (exc. acute promyelocytic leukemia)*

*Drug-Treatable Populations: First line (acute promyelocytic leukemia)*

*Drug-Treatable Populations: Relapsed (acute promyelocytic leukemia)*

#### Bladder Cancer

*Stage: Stage 0*

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Drug-Treatable Populations: Low-risk superficial*

*Drug-Treatable Populations: High-risk superficial*

*Drug-Treatable Populations: Recurrent superficial*

*Drug-Treatable Populations: Muscle-invasive*

*Drug-Treatable Populations: Metastatic*

*Drug-Treatable Populations: Second line*

#### Breast Cancer

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

*Drug-Treatable Populations: [Neo]adjuvant HR+/HER2- postmenopausal*

*Drug-Treatable Populations: [Neo]adjuvant HR+/HER2- premenopausal*

*Drug-Treatable Populations: [Neo]adjuvant HR+/HER2+ postmenopausal*

*Drug-Treatable Populations: [Neo]adjuvant HR+/HER2+ premenopausal*

*Drug-Treatable Populations: [Neo]adjuvant HR-/HER2+*

*Drug-Treatable Populations: [Neo]adjuvant HR-/HER2-*

*Drug-Treatable Populations: 1st line HR+/HER2-*

*Drug-Treatable Populations: 1st line HR-/HER2- (Trip-Negative)*

*Drug-Treatable Populations: 2nd line HR+/HER2-*

*Drug-Treatable Populations: 2nd line HER2+ (HR+ and HR-)*

*Drug-Treatable Populations: 2nd line HR-/HER2- (Trip-Negative)*

*Drug-Treatable Populations: 3rd/4th line HR+/HER2-*

*Drug-Treatable Populations: 3rd/4th line HER2+ (HR+ and HR-)*

*Drug-Treatable Populations: 3rd/4th line HR-/HER2 (Trip-Negative)*

#### Breast cancer: HR+/HER2+ Postmenopausal

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

#### Breast cancer: HR+/HER2+ Premenopausal

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

**Breast cancer: HR+/HER2- Postmenopausal**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

**Breast cancer: HR+/HER2- Premenopausal**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

**Breast cancer: HR-/HER2+**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

**Breast cancer: HR-/HER2-**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

**Cervical Cancer**

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Disease status: Non-drug-treatable*

*Disease status: Drug treatable non-resectable*

*Disease status: Drug treatable resectable*

*Drug-Treatable Populations: Stage I*

*Drug-Treatable Populations: Stage II*

*Drug-Treatable Populations: Stage III*

*Drug-Treatable Populations: Stage IV*

*Drug-Treatable Populations: Second & third lines*

**Chronic Myelogenous Leukemia**

*Stage: Chronic phase (<40 years)*

*Stage: Chronic phase (40 - 74 years)*

*Stage: Chronic phase (75+ years)*

*Stage: Accelerated phase*

*Stage: Blastic phase*

*Drug-Treatable Populations: Chronic phase (< 40 years)*

*Drug-Treatable Populations: Chronic phase (40 - 74 years)*

*Drug-Treatable Populations: Chronic Phase (75+ years)*

*Drug-Treatable Populations: Chronic phase second & subsequent lines*

*Drug-Treatable Populations: Accelerated phase*

*Drug-Treatable Populations: Blastic phase*

**Colon Cancer**

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Disease status: Non-drug-treatable*

**Colorectal Cancer**

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Disease status: Non-drug-treatable*

*Drug-Treatable Populations: Colon cancer stage II*

*Drug-Treatable Populations: Colon cancer stage III*

*Drug-Treatable Populations: Rectal cancer stage II*

*Drug-Treatable Populations: Rectal cancer stage III*

*Drug-Treatable Populations: Stage IV CRC-mut KRAS-first line*

*Drug-Treatable Populations: Stage IV CRC-mut KRAS-second line*

*Drug-Treatable Populations: Stage IV CRC-mut KRAS-third line*

*Drug-Treatable Populations: Stage IV CRC-wt KRAS-first line*

*Drug-Treatable Populations: Stage IV CRC-wt KRAS-second line*

*Drug-Treatable Populations: Stage IV CRC-wt KRAS-third line*

**Esophageal Cancer**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage II*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

**Gastrointestinal Stromal Tumor**

*Stage at diagnosis: Resectable*

*Stage at diagnosis: Unresectable*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Disease status: Non drug-treatable*  
*Drug-Treatable Populations: Localized resectable*  
*Drug-Treatable Populations: Unresectable first-line*  
*Drug-Treatable Populations: Unresectable second-line*  
*Drug-Treatable Populations: Unresectable third-line*

### **Glioma**

*Histology at diagnosis: Ependymoma*  
*Histology at diagnosis: Oligodendroglioma*  
*Histology at diagnosis: Mixed glioma*  
*Histology at diagnosis: Astrocytoma*  
*Astrocytoma: Low-grade astrocytoma*  
*Astrocytoma: Anaplastic astrocytoma*  
*Astrocytoma: Glioblastoma astrocytoma*  
*Resection status: Completely resectable*  
*Resection status: Partially resectable*  
*Resection status: Unresectable*  
*Drug-Treatable Populations: Low grade*  
*Drug-Treatable Populations: High grade*  
*Drug-Treatable Populations: Second line plus*

### **Hepatocellular Carcinoma**

*Stage at diagnosis: Localized resectable*  
*Stage at diagnosis: Localized unresectable or locally advanced*  
*Stage at diagnosis: Advanced*  
*Disease status: Drug-treatable non-resectable*  
*Disease status: Drug-treatable resectable*  
*Disease status: Non drug-treatable*  
*Drug-Treatable Populations: Unresectable/recurrent 1st line*

### **Larynx Cancer**

*Stage: Stage I*  
*Stage: Stage II*  
*Stage: Stage III*  
*Stage: Stage IV*  
*Drug-Treatable Populations: Stage III/IVa,b*  
*Drug-Treatable Populations: Metastatic/recurred*

### **Liver Cancer**

*Stage: Localized resectable*  
*Stage: Localized unresectable or locally advanced*  
*Stage: Advanced*  
*Disease status: Drug-treatable resectable*  
*Disease status: Drug-treatable non-resectable*  
*Disease status: Non drug-treatable*

### **Malignant Melanoma**

*Stage at diagnosis: Stage I*  
*Stage at diagnosis: Stage II*  
*Stage at diagnosis: Stage III*  
*Stage III: IIIa-b*  
*Stage III: IIIc*  
*Stage at diagnosis: Stage IV*  
*Disease Status: Non drug-treatable*  
*Disease Status: Drug-treatable*

*Drug-treatable: Non-resectable*  
*Drug-treatable: Resectable*  
*Drug-Treatable Populations: Adjuvant*  
*Drug-Treatable Populations: First-line unresectable BRAF-positive*  
*Drug-Treatable Populations: First-line unresectable BRAF-negative*  
*Drug-Treatable Populations: Second-line unresectable BRAF-positive*  
*Drug-Treatable Populations: Second-line unresectable BRAF-negative*  
*Drug-Treatable Populations: Third-line unresectable*

### **Multiple Myeloma**

*Stage: Stage I*  
*Stage: Stage II*  
*Stage: Stage III*  
*Drug-Treatable Populations: First line*  
*Drug-Treatable Populations: Second line*  
*Drug-Treatable Populations: Third line*

### **Multiple Myeloma Associated Diseases: Extramedullary Plasmacytoma**

### **Multiple Myeloma Associated Diseases: Monoclonal Gammopathy of Undetermined Significance**

### **Myelodysplastic Syndromes**

*Risk grouping at diagnosis: Low*  
*Risk grouping at diagnosis: Intermediate*  
*Risk grouping at diagnosis: High*  
*Risk grouping at diagnosis: 5q*

### **Nasopharynx Cancer**

*Stage: Stage I*  
*Stage: Stage II*  
*Stage: Stage III*  
*Stage: Stage IV*  
*Treatable Pool: Stage III/IVa,b*  
*Treatable Pool: Metastatic/recurred*

### **Non-Hodgkin's Lymphoma: Chronic Lymphocytic Leukemia**

*CStage at diagnosis: Low risk*  
*Stage at diagnosis: Intermediate risk*  
*Stage at diagnosis: High risk*  
*Drug-Treatable Populations: First line*  
*Drug-Treatable Populations: Second line*  
*Drug-Treatable Populations: Third line*

### **Non-Hodgkin's Lymphoma: Diffuse Large B-cell Lymphoma**

*Stage at diagnosis: Localized*  
*Stage at diagnosis: Regional*  
*Stage at diagnosis: Distant*  
*Drug-Treatable Populations: First line*  
*Drug-Treatable Populations: Second line*  
*Drug-Treatable Populations: Third line*

### **Non-Hodgkin's Lymphoma: Follicular Lymphoma**

*Stage at diagnosis: Localized*  
*Stage at diagnosis: Regional*  
*Stage at diagnosis: Distant*  
*Drug-Treatable Populations: First line*  
*Drug-Treatable Populations: Second line*

*Drug-Treatable Populations: Third line*

### **Non-Hodgkin's Lymphoma: Mantle Cell Lymphoma**

*Stage at diagnosis: Localized*

*Stage at diagnosis: Regional*

*Stage at diagnosis: Distant*

*Drug-Treatable Populations: First line*

*Drug-Treatable Populations: Second line*

*Drug-Treatable Populations: Third line*

### **Non-Small-Cell Lung Cancer**

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Disease status: Non-drug treatable*

*Stage at diagnosis: Stage IA*

*Stage at diagnosis: Stage IB*

*Stage at diagnosis: Stage II*

*Stage at diagnosis: Stage IIIA*

*Stage at diagnosis: Stage IIIB with malignant pleural effusion*

*Stage at diagnosis: Stage IIIB without malignant pleural effusion*

*Stage at diagnosis: Stage IV*

*Drug-Treatable Populations: Stage IB & II*

*Drug-Treatable Populations: Stage IIIA*

*Drug-Treatable Populations: Stage IIIB pleural effusion*

*Drug-Treatable Populations: Stage IIIB pleural effusion & stage IV*

*Drug-Treatable Populations: Second line*

*Drug-Treatable Populations: Third line*

### **Oral Cavity Cancer**

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Drug-Treatable Populations: Stage III/IVa,b*

*Drug-Treatable Populations: Metastatic/recurred*

### **Other Pharynx Cancer**

*Stage: Stage I*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Drug-Treatable Populations: Stage III/IVa,b*

*Drug-Treatable Populations: Metastatic/recurred*

### **Ovarian Cancer**

*Stage: Stage I drug-treated*

*Stage: Stage I non drug-treated*

*Stage: Stage II*

*Stage: Stage III*

*Stage: Stage IV*

*Disease status: Non-drug-treatable*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Drug-Treatable Populations: Early-Stage (I) First-Line*

*Drug-Treatable Populations: Advanced-Stage (II,III, IV) First-Line*

*Drug-Treatable Populations: Second line, Platinum-Sensitive*

*Drug-Treatable Populations: Second line, Platinum-Resistant and -Refractory*

*Drug-Treatable Populations: Third line*

*Drug-Treatable Populations: Fourth line and subsequent lines*

### **Pancreatic Cancer**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage IIa*

*Stage at diagnosis: Stage IIb*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Resection status: Resected*

*Resection status: Unresected*

*Drug-treatable status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Drug-treatable Status: Non drug-treatable*

*Drug-Treatable Populations: Resected*

*Drug-Treatable Populations: Unresectable First-Line*

*Drug-Treatable Populations: Unresectable Second line*

### **Prostate Cancer**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage II*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Non drug-treatable*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Drug-Treatable Populations: Stage I-II (hormone sensitive)*

*Drug-Treatable Populations: Stage III (hormone sensitive)*

*Drug-Treatable Populations: Biochemical recurrence (hormone sensitive)*

*Drug-Treatable Populations: Stage IV (hormone sensitive)*

*Drug-Treatable Populations: Nonmetastatic castrate resistant*

*Drug-Treatable Populations: First line metastatic castrate resistant*

*Drug-Treatable Populations: Second line metastatic castrate resistant*

*Drug-Treatable Populations: Third line metastatic castrate resistant*

### **Rectal Cancer**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage II*

*Stage at diagnosis: Stage III*

*Stage at diagnosis: Stage IV*

*Disease status: Drug-treatable*

*Drug-treatable: Non-resectable*

*Drug-treatable: Resectable*

*Disease status: Non-drug-treatable*

### **Renal Cell Carcinoma**

*Stage at diagnosis: Stage I*

*Stage at diagnosis: Stage II*

*Stage at diagnosis: Stage III*

Stage at diagnosis: Stage IV

Disease status: Non-drug-treatable

Disease status: Drug-treatable

Drug-treatable: Non-resectable

Drug-Treatable Populations: Stage I-III

Drug-Treatable Populations: Stage IV first line

Drug-Treatable Populations: Stage IV second line

Drug-Treatable Populations: Stage IV third line

### Small-Cell Lung Cancer

Severity: Limited

Severity: Extensive

Drug-Treatable Populations: Limited

Drug-Treatable Populations: Extensive

Drug-Treatable Populations: Second line

Drug-Treatable Populations: Third line

### Stomach Cancer

Stage at diagnosis: Stage IA

Stage at diagnosis: Stage IB

Stage at diagnosis: Stage II

Stage at diagnosis: Stage IIIA

Stage at diagnosis: Stage IIIB

Stage at diagnosis: Stage IVA

Stage at diagnosis: Stage IVB

Disease status: Drug-treatable

Drug-treatable: Non-resectable

Drug-treatable: Resectable

Disease status: Non-drug-treatable

Stages HER2-Positive: Stage I-HER2 positive

Stages HER2-Positive: Stage II-HER2 positive

Stages HER2-Positive: Stage III-HER2 positive

Stages HER2-Positive: Stage IV-HER2 positive

Drug-Treatable Populations: Resectable

Drug-Treatable Populations: First line unresectable, HER2-negative

Drug-Treatable Populations: First line unresectable, HER2-positive

Drug-Treatable Populations: Second line, metastatic HER2-negative

Drug-Treatable Populations: Second line, metastatic HER2-positive

## Cardiovascular System

### Acute Coronary Syndrome

Events: ST-Elevation Myocardial Infarction

Events: Non-ST-Elevation Myocardial Infarction

Events: Unstable Angina

Prevalent cases: ST-Elevation Myocardial Infarction

Prevalent cases: Non-ST-Elevation Myocardial Infarction

Prevalent cases: Unstable Angina

### Acute Heart Failure

Diagnosis type: First and second diagnosis

First and second diagnosis: With hypotension

First and second diagnosis: Without hypotension

Diagnosis type: Other diagnosis

Other diagnosis: With hypotension

Other diagnosis: Without hypotension

### Atrial Fibrillation

Subtype: Paroxysmal

Subtype: Persistent

Subtype: Permanent

Acute events: First detected

Acute events: Paroxysm (symptomatic)

Acute events: Paroxysmal progression

Acute events: Recurrent event

Heart failure status: Without heart failure

Heart failure status: With heart failure

With heart failure: NYHA I

With heart failure: NYHA II

With heart failure: NYHA III

With heart failure: NYHA IV

Hypertension status: With hypertension

Hypertension status: Without hypertension

CHADS2 score: CHADS2 score = 0

CHADS2 score: CHADS2 score = 1

CHADS2 score: CHADS2 score = 2

CHADS2 score: CHADS2 score > 2

### Cardiovascular Risk and Hypercholesterolemia

CHD status: CHD or CHD equivalent

CHD or CHD equivalent: LDL less than 100mg/dL

CHD or CHD equivalent: LDL between 100 and 129mg/dL

CHD or CHD equivalent: LDL between 130 and 159mg/dL

CHD or CHD equivalent: LDL 160mg/dL or greater

CHD status: No CHD or CHD equivalent, 0 or 1 risk factors

No CHD or CHD equivalent, 0 or 1 risk factors: LDL less than 100mg/dL

No CHD or CHD equivalent, 0 or 1 risk factors: LDL between 100 and 129mg/dL

No CHD or CHD equivalent, 0 or 1 risk factors: LDL between 130 and 159mg/dL

No CHD or CHD equivalent, 0 or 1 risk factors: LDL 160mg/dL or greater

CHD status: No CHD or CHD equivalent, 2 or more risk factors

No CHD or CHD equivalent, 2 or more risk factors: LDL less than 100mg/dL

No CHD or CHD equivalent, 2 or more risk factors: LDL between 100 and 129mg/dL

No CHD or CHD equivalent, 2 or more risk factors: LDL between 130 and 159mg/dL

No CHD or CHD equivalent, 2 or more risk factors: LDL 160mg/dL or greater

Drug-treatable status: Primary prevention

Drug-treatable status: Secondary prevention

### Chronic Heart Failure

Severity: NYHA I

Severity: NYHA II

Severity: NYHA III

Severity: NYHA IV

## **Coronary Heart Disease**

*Presence of symptoms: Asymptomatic*

*Asymptomatic: Unrecognized PMI*

*Asymptomatic: Atherosclerosis*

*Presence of symptom: Symptomatic*

*Symptomatic: PMI only*

*Symptomatic: Angina only*

*Symptomatic: PMI and angina*

## **Dyslipidemia**

*Treatment status: Drug-treated*

*Drug-treated: High LDL and high TG*

*Drug-treated: High LDL and low HDL*

*Drug-treated: High LDL, high TG, low HDL*

*Drug-treated: High LDL only*

*Drug-treated: High TG and low HDL*

*Drug-treated: High TG only*

*Drug-treated: Low HDL only*

*Drug-treated: Normolipidemic*

*Treatment status: Non drug-treated*

*Non-drug-treated: High LDL and high TG*

*Non-drug-treated: High LDL and low HDL*

*Non-drug-treated: High LDL, high TG, low HDL*

*Non-drug-treated: High LDL only*

*Non-drug-treated: High TG and low HDL*

*Non-drug-treated: High TG only*

*Non-drug-treated: Low HDL only*

## **Elevated C-reactive protein**

### **Hypertension**

*Age group: Age 20-54*

*Age group: Age 55-74*

*Age group: Age 75+*

*Comorbidity: Coronary heart disease*

*Comorbidity: Diabetes*

*Comorbidity: Heart failure*

*Comorbidity: Obesity*

*Comorbidity: Renal impairment*

*Comorbidity: Stroke*

*Drug-treated status: Drug-treated*

*Drug-treated: Stage I*

*Drug-treated: Stage II*

*Drug-treated: Controlled*

*Drug-treated: One antihypertensive controlled*

*Drug-treated: One antihypertensive uncontrolled*

*Drug-treated: Two antihypertensives controlled*

*Drug-treated: Two antihypertensives uncontrolled*

*Drug-treated: Three or more antihypertensives controlled*

*Drug-treated: Three or more antihypertensives uncontrolled*

*Drug-treated status: Non drug-treated*

*Non drug-treated: Stage I*

*Non drug-treated: Stage II*

## **Peripheral Arterial Disease**

*Severity: Stage I*

*Severity: Stage II*

*Severity: Stage III/IV*

## **Peripheral Arterial Thromboembolism**

### **Post-Myocardial Infarction**

### **Prehypertension**

### **Pulmonary Arterial Hypertension**

*Type: Idiopathic*

*Type: Familial*

*Type: Associated*

## **Venous Thromboembolism**

*Diagnosis: DVT*

*Diagnosis: PE*

*Etiology: Cancer-associated*

*Etiology: Not cancer-associated*

*History of recurrence: First ever*

*History of recurrence: Recurrent*

## **Venous Thromboembolism Prophylaxis**

*Nonsurgical: Nonsurgical*

*Surgical: Major general*

*Surgical: Major orthopedic surgery*

*Major orthopedic: Knee or hip arthroplasty*

*Major orthopedic: Orthopedic surgery (not including knee or hip)*

*Surgical: Other surgery*

*Other surgery: Gynecological*

*Other surgery: High risk minor procedure*

*Other surgery: Neurological*

*Other surgery: Urological*

*Other surgery: Vascular*

## **Central Nervous System**

### **Acute Ischemic Stroke**

*Time to presentation of diagnosed population: Three hours or less*

*Time to presentation of diagnosed population: Three to six hours*

*Time to presentation of diagnosed population: Six to nine hours*

*Time to presentation of diagnosed population: Nine to twelve hours*

*Time to presentation of diagnosed population: Twelve to twenty-four hours*

*Time to presentation of diagnosed population: More than twenty-four hours or time unknown*

### **Alcohol Addiction**

*Type: Dependence (with or without abuse)*

*Type: Abuse only*

### **Alzheimer's Disease and Pre-Alzheimer's Disease**

*Type: Pre-Alzheimer's Disease*

*Pre-Alzheimer's Disease: Pre-Alzheimer's Disease 1-2 years*

*Pre-Alzheimer's Disease: Pre-Alzheimer's Disease 3-5 years*

*Type: Alzheimer's Disease*

*Alzheimer's Disease: Mild Alzheimer's Disease*

*Alzheimer's Disease: Moderate Alzheimer's Disease*

*Alzheimer's Disease: Severe Alzheimer's Disease*

**Amyotrophic Lateral Sclerosis\*****Attention-Deficit/Hyperactivity Disorder-Adult****Attention-Deficit/Hyperactivity Disorder-Pediatric**

Subtype: Predominantly inattentive

Combined inattentive and hyperactive: With comorbid oppositional defiant disorder

Combined inattentive and hyperactive: Without comorbid oppositional defiant disorder

Subtype: Predominantly hyperactive/impulsive

Predominantly hyperactive/impulsive: With comorbid oppositional defiant disorder

Predominantly hyperactive/impulsive: Without comorbid oppositional defiant disorder

Subtype: Combined inattentive and hyperactive

Predominantly inattentive : With comorbid oppositional defiant disorder

Predominantly inattentive: Without comorbid oppositional defiant disorder

**Bipolar Depression**

Subtype: BPD I

Subtype: BPD II

Subtype: Subthreshold BPD

**Bipolar Disorder**

Subtype: Bipolar I

Subtype: Bipolar II

Subtype: Sub-threshold BPD

Comorbidities: Major depressive episode

Comorbidities: Generalized anxiety disorder

Comorbidities: Manic episode

**Dementia**

Type: Pure AD

Type: Pure VaD

Type: Pure FTD

Type: Pure LBD

Type: Mixed AD+LBD

Type: Mixed AD+VaD

Type: Mixed AD+HS

Type: Mixed LBD+HS

Type: Mixed FTD+HS

Type: Mixed VaD+HS

Type: Mixed AD+LBD+VaD

Type: Mixed AD+LBD+HS

Type: Mixed AD+HS+VaD

Type: 4 or More

Type: Other

Type: AD

Type: VaD

Type: FTD

Type: LBD

**Epilepsy**

Seizure type: Generalized-onset seizures

Seizure type: Partial-onset seizures

**Generalized Anxiety Disorder**

Comorbidity: With major depressive disorder

Comorbidity: Without major depressive disorder

**Insomnia - DSM IV**

Comorbidity: With depression and/or anxiety

Comorbidity: Without depression and/or anxiety

**Insomnia - RDC**

Comorbidity: With depression and/or anxiety

Comorbidity: Without depression and/or anxiety

**Major Depressive Disorder**

Pain comorbidity: With chronic pain

Pain comorbidity: Without chronic pain

Treatment Status: Drug-treated

Drug-treated: Stage I

Drug-treated: Stage II

Drug-treated: Not treatment resistant

**Mild Cognitive Impairment**

Subtype: Non-amnestic

Subtype: Amnestic

**Minor Depression****Multiple Sclerosis (Relapsing-remitting)****Multiple Sclerosis (Chronic-progressive)**

Type: Primary Progressive

Type: Secondary Progressive

**Narcolepsy****Nicotine Addiction****Obsessive-Compulsive Disorder****Obstructive Sleep Apnea****Opioid Addiction**

Type: Abuse only

Type: Dependence (with or without abuse)

**Panic Disorder**

Comorbidity: With major depressive disorder

Comorbidity: Without major depressive disorder

**Parkinson's Disease**

Dementia Status: With dementia

Dementia Status: Without dementia

Hoehn and Yahr Stage: Stage I

Hoehn and Yahr Stage: Stage II

Hoehn and Yahr Stage: Stage III

Hoehn and Yahr Stage: Stage IV

Hoehn and Yahr Stage: Stage V

**Psychostimulant Addiction**

Type: Dependence (with or without abuse)

Type: Abuse only

**Restless Legs Syndrome**

Severity: Mild

Severity: Moderate

Severity: Severe

Severity: Very severe

## Schizophrenia

*Cognitive impairment: With cognitive impairment*

*Cognitive impairment: Without cognitive impairment*

*Comorbidity: With depression*

*Comorbidity: Without depression*

## Social Anxiety Disorder

*Comorbidity: With major depressive disorder*

*Comorbidity: Without major depressive disorder*

## Traumatic Brain Injury

*Setting: Inpatient*

*Setting: Outpatient*

## Immune & Inflammatory

### Allergic Rhinitis

*Seasonality: Seasonal*

*Seasonality: Perennial*

*Seasonality: Perennial with seasonal exacerbations*

### Ankylosing Spondylitis\*

### Asthma

*Severity: Intermittent*

*Severity: Mild persistent*

*Severity: Moderate persistent*

*Severity: Severe persistent*

### Chronic Obstructive Pulmonary Disease

*Severity: Mild*

*Severity: Moderate*

*Severity: Severe/very severe*

*Treatment status: Treatable patient population*

### Crohn's Disease

*Severity: Remission*

*Severity: Low activity*

*Severity: High activity*

### Eczema/ Atopic Dermatitis

### Gout

*Frequency of acute events: No acute events annually*

*Frequency of acute events: One or more acute events annually*

*One or more acute events annually: One acute event annually*

*One or more acute events annually: Two acute events annually*

*One or more acute events annually: Three or more acute events annually*

### Gout (Acute Flares)

### Juvenile Idiopathic Arthritis

### Osteoarthritis

*Severity: Asymptomatic*

*Severity: Symptomatic*

### Psoriasis

*Severity: Remission*

*Severity: Mild*

*Severity: Moderate*

*Severity: Severe*

*Treatment opportunities: Mild psoriasis*

*Treatment opportunities: Moderate to severe psoriasis*

### Psoriatic Arthritis

*Joint involvement: Axial only*

*Joint involvement: Axial and peripheral*

*Joint involvement: Peripheral*

### Reactive Arthritis\*

### Rheumatoid Arthritis

### Sarcoidosis\*

*Race: African American*

*Race: Non-African American*

### Scleroderma (Systemic Sclerosis)\*

### Sjogren's Syndrome\*

*Subtype: Primary*

*Subtype: Secondary*

### Systemic Lupus Erythematosus

### Ulcerative Colitis

*Severity: Mild*

*Severity: Moderate*

*Severity: Severe*

### Urticaria

## Infectious Disease

### Acute Exacerbations of Chronic Bronchitis

*Treatment setting: Inpatient*

*Treatment setting: Outpatient*

### Clostridium Difficile Infection

*Healthcare setting: Hospital*

*Healthcare setting: Nursing home*

*Recurrence Status: First episodes*

*Recurrence Status: Recurring episodes*

### Community-Acquired Methicillin-Resistant Staphylococcus aureus

*Infection site: SSTI*

*Infection site: Wound*

*Infection site: Pneumonia*

*Infection site: UTI*

*Infection site: Sinus*

*Infection site: BSI*

*Infection site: Other*

*Patient Care Setting: Inpatient*

*Patient Care Setting: Outpatient*

### Community-Acquired Pneumonia

*Patient Care Setting: Inpatient*

*Patient Care Setting: Outpatient*

### Complicated Skin and Skin Structure Infections

*Pathogens: Staphylococcus aureus*

*Pathogens: Coagulase negative staphylococcus*

*Pathogens: Enterococcus spp.*

*Pathogens: Escherichia coli*

*Pathogens: Klebsiella spp.*

*Pathogens: Pseudomonas spp.*

*Pathogens: Acinetobacter spp.*

*Pathogens: Other pathogens*

### **Hepatitis B**

*Laboratory measure: Hbe Antigen-positive*

*Laboratory measure: Hbe Antigen-negative*

### **Hepatitis C**

*Laboratory measure: Non-viremic*

*Laboratory measure: Viremic*

### **Herpes Zoster**

#### **Hospital-Acquired BSI**

*Pathogens: S. aureus*

*Pathogens: CoNS*

*Pathogens: Enterococcus spp.*

*Pathogens: E. Coli*

*Pathogens: Klebsiella spp.*

*Pathogens: Pseudomonas spp.*

*Pathogens: Acinetobacter spp.*

*Pathogens: Other pathogens*

#### **Hospital-Acquired Methicillin-Resistant Staphylococcus aureus**

*Infection Site: BSI*

*Infection Site: Pneumonia*

*Infection Site: SSI & cSSSI*

*Infection Site: UTI*

#### **Hospital-Acquired Pneumonia**

*Type: HCAP*

*HCAP: S. aureus*

*HCAP: Pseudomonas spp.*

*HCAP: E. Coli*

*HCAP: Klebsiella spp.*

*HCAP: Acinetobacter spp.*

*HCAP: Other pathogens*

*Type: HAP*

*HAP: S. aureus*

*HAP: Pseudomonas spp.*

*HAP: E. Coli*

*HAP: Klebsiella spp.*

*HAP: Acinetobacter spp.*

*HAP: Other pathogens*

*Type: VAP*

*VAP: S. aureus*

*VAP: Pseudomonas spp.*

*VAP: E. Coli*

*VAP: Klebsiella spp.*

*VAP: Acinetobacter spp.*

*VAP: Other pathogens*

#### **Hospital-Acquired SSI+cSSSI**

*Type: SSI*

*Type: cSSSI*

*Pathogens: S. aureus*

*Pathogens: CoNS*

*Pathogens: Enterococcus spp.*

*Pathogens: E. Coli*

*Pathogens: Klebsiella spp.*

*Pathogens: Pseudomonas spp.*

*Pathogens: Acinetobacter spp.*

*Pathogens: Other pathogens*

#### **Hospital-Acquired UTI**

*Pathogens: S. aureus*

*Pathogens: CoNS*

*Pathogens: Enterococcus spp.*

*Pathogens: E. Coli*

*Pathogens: Klebsiella spp.*

*Pathogens: Pseudomonas spp.*

*Pathogens: Acinetobacter spp.*

*Pathogens: Other pathogens*

#### **Human Immunodeficiency Virus**

#### **Influenza**

#### **Sepsis**

*Severity: Septic shock*

*Severity: Severe sepsis*

*Severity: Sepsis NOS*

*Culture: Positive*

*Culture: Negative*

#### **Severe Fungal Infections (susceptible populations)**

*Susceptible Population: Neutropenia*

*Susceptible Population: Acute leukemia*

*Susceptible Population: Stem cell transplant*

*Susceptible Population: Solid organ transplant*

*Susceptible Population: HIV*

*Susceptible Population: Postoperative/surgical*

#### **Severe Fungal Infections (candidiasis)**

*Susceptible Population: Neutropenia*

*Susceptible Population: Acute leukemia*

*Susceptible Population: Stem cell transplant*

*Susceptible Population: Solid organ transplant*

*Susceptible Population: HIV*

*Susceptible Population: Postoperative/surgical*

#### **Severe Fungal Infections (aspergillosis)**

*Susceptible Population: Neutropenia*

*Susceptible Population: Acute leukemia*

*Susceptible Population: Stem cell transplant*

*Susceptible Population: Solid organ transplant*

*Susceptible Population: HIV*

#### **Sinusitis**

*Type: Acute sinusitis*

*Type: Chronic sinusitis*

## **Metabolic Disorders**

#### **Diabetic End Stage Renal Disease**

#### **Diabetic Nephropathy**

*Severity: Macroalbuminuria*

*Severity: Microalbuminuria*

## Diabetic Retinopathy

Subtype: Proliferative

Subtype: Non-proliferative

Other diagnosis: With macular edema

Other diagnosis: Without macular edema

## Impaired Glucose Tolerance

### Metabolic Syndrome (AHA/NHLB)

FPG: < 100 mg/dL

FPG: 100 < 126 mg/dL

FPG: >126 mg/dL

Components: Obesity hypertension TG HDL IFG

Components: Obesity hypertension TG HDL

Components: Obesity hypertension TG IFG

Components: Obesity hypertension HDL IFG

Components: Obesity TG HDL IFG

Components: Hypertension TG HDL IFG

Components: Obesity hypertension TG

Components: Obesity hypertension HDL

Components: Obesity hypertension IFG

Components: Obesity TG HDL

Components: Obesity TG IFG

Components: Obesity HDL IFG

Components: Hypertension TG HDL

Components: Hypertension TG IFG

Components: Hypertension HDL IFG

Components: TG HDL IFG

### Metabolic Syndrome (IDF)

FPG: < 100 mg/dL

FPG: 100<126 mg/dL

FPG: >126 mg/dL

Components: Obesity hypertension TG HDL IFG

Components: Obesity hypertension TG HDL

Components: Obesity hypertension TG IFG

Components: Obesity hypertension HDL IFG

Components: Obesity TG HDL IFG

Components: Obesity hypertension TG

Components: Obesity hypertension HDL

Components: Obesity hypertension IFG

Components: Obesity TG HDL

Components: Obesity TG IFG

Components: Obesity HDL IFG

## Obesity

Severity: Class I

Severity: Class II

Severity: Class III

## Osteopenia

## Osteoporosis

## Overweight

## Type 1 Diabetes

## Type 2 Diabetes

BMI status: Normal (18.5-24.9)

BMI status: Overweight (25-29.9)

BMI status: Obese Class 1 (30-34.9)

BMI status: Obese Class 2 (35-39.9)

BMI status: Obese Class 3 (>=40)

## Other High Interest

### Age-Related Macular Degeneration

Type: Dry

Type: Wet

### Benign Prostatic Hyperplasia and Male Lower Urinary Tract Syndrome: BPH

Severity: Diagnosed BPH with mild symptoms

Severity: Diagnosed BPH with moderate symptoms

Severity: Diagnosed BPH with severe symptoms

Comorbidity: Diagnosed BPH with comorbid erectile dysfunction

Comorbidity: Diagnosed BPH with comorbid hypertension

### Benign Prostatic Hyperplasia and Male Lower Urinary Tract Syndrome: male LUTS

Severity: Moderate

Severity: Severe

Mild BPH and moderate and severe LUTS: Mild BPH and moderate and severe LUTS

Comorbid Erectile Dysfunction: Moderate LUTS with comorbid erectile dysfunction

Comorbid Erectile Dysfunction: Moderate LUTS without comorbid erectile dysfunction

Comorbid Erectile Dysfunction: Severe LUTS with comorbid erectile dysfunction

Comorbid Erectile Dysfunction: Severe LUTS without comorbid erectile dysfunction

Comorbid Erectile Dysfunction: Severe LUTS without comorbid erectile dysfunction

## Cystic Fibrosis\*

## Erectile Dysfunction

## Glaucoma (Select Types)\*

Type: Congenital glaucoma

Type: Primary open angle glaucoma

## Irritable Bowel Syndrome

Subtype: Constipation predominant

Subtype: Diarrhea predominant

Subtype: Mixed

## Overactive Bladder

## Urinary Incontinence (Stress)

## Pain Management

### Acute Low Back Pain

Severity: Acute pain (<2wks)

Severity: Subacute pain (2wks-3mnths)

### Acute Neck Pain

Severity: Acute pain (<2wks)

Severity: Subacute pain (2wks-3mnths)

**Chronic Daily Headache**

*Subtype: No transformed migraine*

*Subtype: Transformed migraine*

**Chronic Low Back Pain**

*Comorbidity: Without sciatica*

*Comorbidity: With sciatica*

**Diabetic Neuropathy****Dysmenorrhea**

*Severity: Mild*

*Severity: Moderate/severe*

**Fibromyalgia**

*Comorbidity: With depression*

*Comorbidity: Without depression*

**HIV/AIDS-Related Neuropathic Pain****Migraine Chronic (Prophylaxis)****Migraine Episodic (Prophylaxis)****Musculoskeletal Pain (Acute)**

*Number of sites: One site*

*Number of sites: Two-three sites*

*Number of sites: Four or more sites*

**Musculoskeletal Pain (Sub-Acute)**

*Number of sites: One site*

*Number of sites: Two-three sites*

*Number of sites: Four or more sites*

**Neuropathic Back Pain (NEW 2012)****Osteoarthritic Pain****Painful Diabetic Neuropathy****Post-operative pain**

*Procedure type: Appendectomy (excluding incidental)*

*Procedure type: Cesarean section*

*Procedure type: Cholecystectomy*

*Procedure type: Coronary artery bypass graft*

*Procedure type: Debridement of wound, burn, or infection*

*Procedure type: Hysterectomy and/or oophorectomy*

*Hysterectomy and/or oophorectomy: Hysterectomy only*

*Hysterectomy and/or oophorectomy: Oophorectomy only*

*Hysterectomy and/or oophorectomy: Hysterectomy and oophorectomy*

*Procedure type: Laminectomy/excision of intervertebral disk*

*Procedure type: Lysis of peritoneal adhesions*

*Procedure type: Mastectomy*

*Procedure type: Orthopedic Procedures*

*Orthopedic Procedures: Other orthopedic procedures*

*Orthopedic Procedures: Hip or knee replacement*

*Procedure type: Partial colectomy*

*Procedure type: Prostatectomy*

**Postherpetic Neuralgia****Rheumatoid Arthritic Pain**

A Decision Resources Group Company

[www.DecisionResources.com](http://www.DecisionResources.com)